Tao Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tao Luo has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
Jia Ge
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China Chongqing China
12 shared publicationsYang Lan
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China Chongqing China
11 shared publicationsJiao Wang
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China Chongqing China
8 shared publicationsLihong Wang
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China Chongqing China
8 shared publications- Xiu-Wu Bian
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China
7 shared publications Mei Liang
Bio‐Bank of Southwest Hospital Third Military Medical University (Army Medical University) Chongqing 400038 China
6 shared publications
Latest Publications
- 6 April 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70073
Challenge of Diagnostic Criteria for Diffuse Hemispheric Glioma (DHG), H3 G34‐Mutant: A Case of DHG Without H3.3 Gene Alteration
We present a case of diffuse hemispheric glioma (DHG), H3 G34‐mutant, NEC. Postoperative histological examination and DNA sequencing detected some features consistent with DHG, H3 G34‐mutant; however, no canonical H3 alterations or ATRX variants were detected. The diagnosis could only be established based on the DNA methylation profiling result. In light of these distinctive molecular findings, we propose some insights into the current WHO diagnostic criteria for DHG H3‐G34 and emphasise the value of comprehensive molecular diagnosis.
- 6 April 2026
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 52 (2) , e70073
Challenge of Diagnostic Criteria for Diffuse Hemispheric Glioma (DHG), H3 G34‐Mutant: A Case of DHG Without H3.3 Gene Alteration
We present a case of diffuse hemispheric glioma (DHG), H3 G34‐mutant, NEC. Postoperative histological examination and DNA sequencing detected some features consistent with DHG, H3 G34‐mutant; however, no canonical H3 alterations or ATRX variants were detected. The diagnosis could only be established based on the DNA methylation profiling result. In light of these distinctive molecular findings, we propose some insights into the current WHO diagnostic criteria for DHG H3‐G34 and emphasise the value of comprehensive molecular diagnosis.
- 25 March 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (3) , 314-321
Multinodular and vacuolating neuronal tumor: molecular genetics and DNA methylation analysis of 12 cases
Multinodular and vacuolating neuronal tumor (MVNT) was recognized as a distinct neuronal tumor entity in the revision of the 2021 World Health Organization (WHO) Classification of Tumors of the CNS. In this study, we retrospectively analyzed 12 surgical cases, two of which exhibited ganglioglioma (GG)‐like components. The cohort consisted of eight male and four female patients, with a median age of 31 years (age range: 18–53 years). Seizures were the most common clinical presentation, followed by headache and dizziness. Three patients were incidentally identified during physical examination. Ten tumors were located in the cerebral hemisphere, and the remaining two were found in the cerebellum and thalamus, respectively. Histopathological examination revealed clusters of neuroepithelial cells with large amphophilic vacuolated cytoplasm and eccentrically placed round nuclei containing prominent nucleoli. Immunohistochemically, these vacuolated cells were positive for OLIG2, MAP2, SYN and SOX10, and negative for GFAP and NEUN. DNA sequencing analysis identified no mutations in IDH1 , IDH2 , BRAF V600E, TERT promoter, or EGFR genes. Among the cohort, three cases harbored FGFR2 mutations, and FGFR2 :: INA gene fusion was detected in both MVNT and GG‐like components. Two cases carried BRAF mutation, and one case exhibited MAP2K1 mutation. A novel BCAN::NTRK1 (exon 12–exon 9) gene fusion was identified in one case. DNA methylation profiling of eight cases revealed that none matched with a known CNS tumor type. Six cases formed a separate methylation cluster, suggesting a potential novel molecular subtype, while the remaining two cases exhibited transcriptional similarities to supratentorial pilocytic astrocytoma and rosette‐forming glioneuronal tumor (RGNT), respectively. Postoperatively, all patients remained seizure free with no evidence of tumor progression. Only one patient died 16 months after surgery due to an unrelated traffic accident. © 2026 The Pathological Society of Great Britain and Ireland.
- 25 March 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (3) , 314-321
Multinodular and vacuolating neuronal tumor: molecular genetics and DNA methylation analysis of 12 cases
Multinodular and vacuolating neuronal tumor (MVNT) was recognized as a distinct neuronal tumor entity in the revision of the 2021 World Health Organization (WHO) Classification of Tumors of the CNS. In this study, we retrospectively analyzed 12 surgical cases, two of which exhibited ganglioglioma (GG)‐like components. The cohort consisted of eight male and four female patients, with a median age of 31 years (age range: 18–53 years). Seizures were the most common clinical presentation, followed by headache and dizziness. Three patients were incidentally identified during physical examination. Ten tumors were located in the cerebral hemisphere, and the remaining two were found in the cerebellum and thalamus, respectively. Histopathological examination revealed clusters of neuroepithelial cells with large amphophilic vacuolated cytoplasm and eccentrically placed round nuclei containing prominent nucleoli. Immunohistochemically, these vacuolated cells were positive for OLIG2, MAP2, SYN and SOX10, and negative for GFAP and NEUN. DNA sequencing analysis identified no mutations in IDH1 , IDH2 , BRAF V600E, TERT promoter, or EGFR genes. Among the cohort, three cases harbored FGFR2 mutations, and FGFR2 :: INA gene fusion was detected in both MVNT and GG‐like components. Two cases carried BRAF mutation, and one case exhibited MAP2K1 mutation. A novel BCAN::NTRK1 (exon 12–exon 9) gene fusion was identified in one case. DNA methylation profiling of eight cases revealed that none matched with a known CNS tumor type. Six cases formed a separate methylation cluster, suggesting a potential novel molecular subtype, while the remaining two cases exhibited transcriptional similarities to supratentorial pilocytic astrocytoma and rosette‐forming glioneuronal tumor (RGNT), respectively. Postoperatively, all patients remained seizure free with no evidence of tumor progression. Only one patient died 16 months after surgery due to an unrelated traffic accident. © 2026 The Pathological Society of Great Britain and Ireland.
- Open Access
- 4 February 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Two pediatric supratentorial ependymal tumors with novel PLAG1 fusions
The 2021 World Health Organization (WHO) Classification of Central Nervous System (CNS) classification formalized routine molecular profiling, and DNA-meth
- 4 February 2026
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Open AccessTwo pediatric supratentorial ependymal tumors with novel PLAG1 fusions
The 2021 World Health Organization (WHO) Classification of Central Nervous System (CNS) classification formalized routine molecular profiling, and DNA-meth
- Open Access
- 17 September 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (2) , e70040
Identification of a distinct epigenetic subgroup with inferior PFS in intracranial mesenchymal tumors with FET :: CREB fusion
Intracranial mesenchymal tumors (IMTs) with FET::CREB fusion are newly recognized molecular entities, provisionally classified into subgroups A and B. Although Group B has been partially characterized, the clinicopathological and molecular heterogeneity of Group A remains poorly defined. This study aimed to conduct an integrated analysis of 6 newly diagnosed and 20 previously reported IMTs with FET::CREB fusion. Notably, Group A was further stratified into two distinct entities A1 and A2 based on unsupervised methylation profiling. Compared to Group A1, Group A2 demonstrated significantly shorter progression‐free survival (PFS), a higher proportion of male patients, and less frequent occurrence of myxoid‐rich stroma. Amplification of 10p15.3 was frequently observed in Group A2. Furthermore, GLUT‐1 could serve as a potential diagnostic indicator in IMTs with FET::CREB fusion. Overall, we identified a new subgroup of IMTs with FET::CREB fusion with poor PFS and distinct clinicopathological and molecular features, offering actionable insights to refine therapeutic strategies and improve risk stratification in this emerging diagnostic category.
- 17 September 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (2) , e70040
Open AccessIdentification of a distinct epigenetic subgroup with inferior PFS in intracranial mesenchymal tumors with FET :: CREB fusion
Intracranial mesenchymal tumors (IMTs) with FET::CREB fusion are newly recognized molecular entities, provisionally classified into subgroups A and B. Although Group B has been partially characterized, the clinicopathological and molecular heterogeneity of Group A remains poorly defined. This study aimed to conduct an integrated analysis of 6 newly diagnosed and 20 previously reported IMTs with FET::CREB fusion. Notably, Group A was further stratified into two distinct entities A1 and A2 based on unsupervised methylation profiling. Compared to Group A1, Group A2 demonstrated significantly shorter progression‐free survival (PFS), a higher proportion of male patients, and less frequent occurrence of myxoid‐rich stroma. Amplification of 10p15.3 was frequently observed in Group A2. Furthermore, GLUT‐1 could serve as a potential diagnostic indicator in IMTs with FET::CREB fusion. Overall, we identified a new subgroup of IMTs with FET::CREB fusion with poor PFS and distinct clinicopathological and molecular features, offering actionable insights to refine therapeutic strategies and improve risk stratification in this emerging diagnostic category.
- Open Access
- 8 April 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (7) , 104168
Comparison of Fluorescence In Situ Hybridization, Next-Generation Sequencing, and DNA Methylation Microarray for Copy Number Variation Assessment in Gliomas
- 8 April 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (7) , 104168
Open AccessComparison of Fluorescence In Situ Hybridization, Next-Generation Sequencing, and DNA Methylation Microarray for Copy Number Variation Assessment in Gliomas
- Open Access
- 31 October 2023
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-9
Combination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
The genomic instability (GI) /homologous recombination deficiency (HRD) score, calculated as the sum of the events of loss of heterozygosity (LOH), large-scale state transition (LST) and telomere allele imbalance (TAI), is used to guide the choice of treatment in several cancers, but its relationship with genomic features, clinicopathological characteristics and prognosis in lung cancer is poorly understood, which could lead to population bias in prospective studies. We retrospectively analyzed 1011 lung cancer patients whose tumor samples were successfully profiled by high-throughput sequencing panel including GI/HRD score. Alterations of many cancer suppressor genes were associated with higher GI/HRD scores, biallelic inactivation of TP53 was correlated with a high GI/HRD score. A combination of two gene alterations exhibited a higher GI/HRD scores than single gene alterations. The GI/HRD score was associated with advanced stages in lung adenocarcinoma but not in lung squamous cell carcinoma. Furthermore, patients with higher GI/HRD scores had significantly shorter overall survival and progression-free survival than patients with lower GI/HRD scores. Finally, patients with a combination of a higher GI/HRD scores and TP53 alteration exhibited an extremely poor prognosis compared with patients with a lower GI/HRD scores and wild-type TP53 (overall survival, training cohort, hazard ratio (HR) = 8.56, P < 0.001; validation cohort, HR = 6.47, P < 0.001; progression-free survival, HR = 4.76, P < 0.001). Our study revealed the prognostic value of the GI/HRD score in lung adenocarcinoma, but not for all lung cancer. Moreover, the combination of the GI/HRD score and TP53 status could be a promising strategy to predict the prognosis of patients with lung adenocarcinoma.
- 31 October 2023
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-9
Open AccessCombination of genomic instability score and TP53 status for prognosis prediction in lung adenocarcinoma
The genomic instability (GI) /homologous recombination deficiency (HRD) score, calculated as the sum of the events of loss of heterozygosity (LOH), large-scale state transition (LST) and telomere allele imbalance (TAI), is used to guide the choice of treatment in several cancers, but its relationship with genomic features, clinicopathological characteristics and prognosis in lung cancer is poorly understood, which could lead to population bias in prospective studies. We retrospectively analyzed 1011 lung cancer patients whose tumor samples were successfully profiled by high-throughput sequencing panel including GI/HRD score. Alterations of many cancer suppressor genes were associated with higher GI/HRD scores, biallelic inactivation of TP53 was correlated with a high GI/HRD score. A combination of two gene alterations exhibited a higher GI/HRD scores than single gene alterations. The GI/HRD score was associated with advanced stages in lung adenocarcinoma but not in lung squamous cell carcinoma. Furthermore, patients with higher GI/HRD scores had significantly shorter overall survival and progression-free survival than patients with lower GI/HRD scores. Finally, patients with a combination of a higher GI/HRD scores and TP53 alteration exhibited an extremely poor prognosis compared with patients with a lower GI/HRD scores and wild-type TP53 (overall survival, training cohort, hazard ratio (HR) = 8.56, P < 0.001; validation cohort, HR = 6.47, P < 0.001; progression-free survival, HR = 4.76, P < 0.001). Our study revealed the prognostic value of the GI/HRD score in lung adenocarcinoma, but not for all lung cancer. Moreover, the combination of the GI/HRD score and TP53 status could be a promising strategy to predict the prognosis of patients with lung adenocarcinoma.
- Open Access
- 25 September 2023
- Published by Taylor & Francis in Autophagy
- Vol. 20 (2) , 295-310
KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function
AO: acridine orange; ATM: ATM serine/threonine kinase; CHEK1: checkpoint kinase 1; CHEK2: checkpoint kinase 2; CI: combination index; DMSO: dimethyl sulfoxide; DSBs: double-strand breaks; GBM: glioblastoma; HR: homologous recombination; H2AX: H2A.X variant histone; IHC: immunohistochemistry; LAPTM4B: lysosomal protein transmembrane 4 beta; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; PARP: poly(ADP-ribose) polymerase; RAD51: RAD51 recombinase; SQSTM1: sequestosome 1; SSBs: single-strand breaks; RNF168: ring finger protein 168; XPO1: exportin 1.
- 25 September 2023
- Published by Taylor & Francis in Autophagy
- Vol. 20 (2) , 295-310
Open AccessKPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function
AO: acridine orange; ATM: ATM serine/threonine kinase; CHEK1: checkpoint kinase 1; CHEK2: checkpoint kinase 2; CI: combination index; DMSO: dimethyl sulfoxide; DSBs: double-strand breaks; GBM: glioblastoma; HR: homologous recombination; H2AX: H2A.X variant histone; IHC: immunohistochemistry; LAPTM4B: lysosomal protein transmembrane 4 beta; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; PARP: poly(ADP-ribose) polymerase; RAD51: RAD51 recombinase; SQSTM1: sequestosome 1; SSBs: single-strand breaks; RNF168: ring finger protein 168; XPO1: exportin 1.
- Open Access
- 25 March 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 548
Cyclin-Dependent Kinase Inhibitor 2A/B Homozygous Deletion Prediction and Survival Analysis
Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) homozygous deletion was a significant prognostic factor for gliomas and affected the treatment strategy. However, the radiomic features of CDKN2A/B homozygous deletion in gliomas have not been developed, and whether the radiomic features and molecular subgroups can provide prognostic value in low-grade gliomas (LGGs) has yet to be studied. Thus, this study aimed to develop a predictive model of CDKN2A/B in gliomas and investigate the prognostic value of this biomarker and radiomic features in isocitrate dehydrogenase (IDH)-mutant LGGs. First, we developed the predictive model of CDKN2A/B homozygous deletion in 292 patients. The results revealed that radiomic features predict CDKN2A/B homozygous deletion with high accuracy and reliability. Subsequently, the prognostic survival models of 104 patients (IDH-mutant LGGs) were established, which provided an essential value for prognostic evaluation and indicated that CDKN2A/B homozygous deletion can be used as an independent predictor of prognosis in LGGs.
- 25 March 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (4) , 548
Open AccessCyclin-Dependent Kinase Inhibitor 2A/B Homozygous Deletion Prediction and Survival Analysis
Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) homozygous deletion was a significant prognostic factor for gliomas and affected the treatment strategy. However, the radiomic features of CDKN2A/B homozygous deletion in gliomas have not been developed, and whether the radiomic features and molecular subgroups can provide prognostic value in low-grade gliomas (LGGs) has yet to be studied. Thus, this study aimed to develop a predictive model of CDKN2A/B in gliomas and investigate the prognostic value of this biomarker and radiomic features in isocitrate dehydrogenase (IDH)-mutant LGGs. First, we developed the predictive model of CDKN2A/B homozygous deletion in 292 patients. The results revealed that radiomic features predict CDKN2A/B homozygous deletion with high accuracy and reliability. Subsequently, the prognostic survival models of 104 patients (IDH-mutant LGGs) were established, which provided an essential value for prognostic evaluation and indicated that CDKN2A/B homozygous deletion can be used as an independent predictor of prognosis in LGGs.
- Open Access
- 26 July 2022
- Published by Wiley in Advanced Science
- Vol. 9 (27) , e2105938
ASCL2 Maintains Stemness Phenotype through ATG9B and Sensitizes Gliomas to Autophagy Inhibitor
Autophagy is a highly conserved process that is vital for tumor progression and treatment response. Although autophagy is proposed to maintain the stemness phenotype in adult diffuse glioma, the molecular basis of the link between autophagy and stemness is poorly understood, which makes it impossible to effectively screen for the population that will benefit from autophagy‐targeted treatment. Here, ATG9B as essential for self‐renewal capacity and tumor‐propagation potential is identified. Notably, ASCL2 transcriptionally regulates the expression of ATG9B to maintain stemness properties. The ASCL2‐ATG9B axis is an independent prognostic biomarker and indicator of autophagic activity. Furthermore, the highly effective blood–brain barrier (BBB)‐permeable autophagy inhibitor ROC‐325, which can significantly inhibit the progression of ASCL2‐ATG9B axisHigh gliomas as a single agent is investigated. These data demonstrate that a new ASCL2‐ATG9B signaling axis is crucial for maintaining the stemness phenotype and tumor progression, revealing a potential autophagy inhibition strategy for adult diffuse gliomas.
- 26 July 2022
- Published by Wiley in Advanced Science
- Vol. 9 (27) , e2105938
Open AccessASCL2 Maintains Stemness Phenotype through ATG9B and Sensitizes Gliomas to Autophagy Inhibitor
Autophagy is a highly conserved process that is vital for tumor progression and treatment response. Although autophagy is proposed to maintain the stemness phenotype in adult diffuse glioma, the molecular basis of the link between autophagy and stemness is poorly understood, which makes it impossible to effectively screen for the population that will benefit from autophagy‐targeted treatment. Here, ATG9B as essential for self‐renewal capacity and tumor‐propagation potential is identified. Notably, ASCL2 transcriptionally regulates the expression of ATG9B to maintain stemness properties. The ASCL2‐ATG9B axis is an independent prognostic biomarker and indicator of autophagic activity. Furthermore, the highly effective blood–brain barrier (BBB)‐permeable autophagy inhibitor ROC‐325, which can significantly inhibit the progression of ASCL2‐ATG9B axisHigh gliomas as a single agent is investigated. These data demonstrate that a new ASCL2‐ATG9B signaling axis is crucial for maintaining the stemness phenotype and tumor progression, revealing a potential autophagy inhibition strategy for adult diffuse gliomas.
- 25 July 2022
- Published by Wiley in The Journal of Pathology
- Vol. 258 (2) , 121-135
A map of the spatial distribution and tumour‐associated macrophage states in glioblastoma and grade 4 IDH‐mutant astrocytoma
Tumour‐associated macrophages (TAMs) abundantly infiltrate high‐grade gliomas and orchestrate immune response, but their diversity in isocitrate dehydrogenase (IDH)‐differential grade 4 gliomas remains largely unknown. This study aimed to dissect the transcriptional states, spatial distribution, and clinicopathological significance of distinct monocyte‐derived TAM (Mo‐TAM) and microglia‐derived TAM (Mg‐TAM) clusters across glioblastoma‐IDH‐wild type and astrocytoma‐IDH‐mutant‐grade 4 (Astro‐IDH‐mut‐G4). Single‐cell RNA sequencing was performed on four cases of human glioblastoma and three cases of Astro‐IDH‐mut‐G4. Cell clustering, single‐cell regulatory network inference, and gene set enrichment analysis were performed to characterize the functional states of myeloid clusters. The spatial distribution of TAM subsets was determined in human glioma tissues using multiplex immunostaining. The prognostic value of different TAM‐cluster specific gene sets was evaluated in the TCGA glioma cohort. Profiling and unbiased clustering of 24,227 myeloid cells from glioblastoma and Astro‐IDH‐mut‐G4 identified nine myeloid cell clusters including monocytes, six Mo/Mg‐TAM subsets, dendritic cells, and proliferative myeloid clusters. Different Mo/Mg‐TAM clusters manifest functional and transcriptional diversity controlled by specific regulons. Multiplex immunostaining of subset‐specific markers identified spatial enrichment of distinct TAM clusters at peri‐vascular/necrotic areas in tumour parenchyma or at the tumour–brain interface. Glioblastoma harboured a substantially higher number of monocytes and Mo‐TAM‐inflammatory clusters, whereas Astro‐IDH‐mut‐G4 had a higher proportion of TAM subsets mediating antigen presentation. Glioblastomas with a higher proportion of monocytes exhibited a mesenchymal signature, increased angiogenesis, and worse patient outcome. Our findings provide insight into myeloid cell diversity and its clinical relevance in IDH‐differential grade 4 gliomas, and may serve as a resource for immunotherapy development. © 2022 The Pathological Society of Great Britain and Ireland.
- 25 July 2022
- Published by Wiley in The Journal of Pathology
- Vol. 258 (2) , 121-135
A map of the spatial distribution and tumour‐associated macrophage states in glioblastoma and grade 4 IDH‐mutant astrocytoma
Tumour‐associated macrophages (TAMs) abundantly infiltrate high‐grade gliomas and orchestrate immune response, but their diversity in isocitrate dehydrogenase (IDH)‐differential grade 4 gliomas remains largely unknown. This study aimed to dissect the transcriptional states, spatial distribution, and clinicopathological significance of distinct monocyte‐derived TAM (Mo‐TAM) and microglia‐derived TAM (Mg‐TAM) clusters across glioblastoma‐IDH‐wild type and astrocytoma‐IDH‐mutant‐grade 4 (Astro‐IDH‐mut‐G4). Single‐cell RNA sequencing was performed on four cases of human glioblastoma and three cases of Astro‐IDH‐mut‐G4. Cell clustering, single‐cell regulatory network inference, and gene set enrichment analysis were performed to characterize the functional states of myeloid clusters. The spatial distribution of TAM subsets was determined in human glioma tissues using multiplex immunostaining. The prognostic value of different TAM‐cluster specific gene sets was evaluated in the TCGA glioma cohort. Profiling and unbiased clustering of 24,227 myeloid cells from glioblastoma and Astro‐IDH‐mut‐G4 identified nine myeloid cell clusters including monocytes, six Mo/Mg‐TAM subsets, dendritic cells, and proliferative myeloid clusters. Different Mo/Mg‐TAM clusters manifest functional and transcriptional diversity controlled by specific regulons. Multiplex immunostaining of subset‐specific markers identified spatial enrichment of distinct TAM clusters at peri‐vascular/necrotic areas in tumour parenchyma or at the tumour–brain interface. Glioblastoma harboured a substantially higher number of monocytes and Mo‐TAM‐inflammatory clusters, whereas Astro‐IDH‐mut‐G4 had a higher proportion of TAM subsets mediating antigen presentation. Glioblastomas with a higher proportion of monocytes exhibited a mesenchymal signature, increased angiogenesis, and worse patient outcome. Our findings provide insight into myeloid cell diversity and its clinical relevance in IDH‐differential grade 4 gliomas, and may serve as a resource for immunotherapy development. © 2022 The Pathological Society of Great Britain and Ireland.